Supplementary appendix

Transkript

1 Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Pfirrmann M, Ehninger G, Thiede C, et al. Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial. Lancet Oncol 2011; published online Dec 23. DOI: /S (11)

2 Supplementary figures Favourable-score group, 3-year survival: 0 61 [0 54; 0 67] Intermediate-score group, 3-year survival: 0 38 [0 31; 0 44] Probability of disease-free survival Unfavourable-score group, 3-year survival: 0 14 [0 07; 0 24] Score groups with number at risk Fav Interm Unfav Supplementary Figure 1A: Kaplan-Meier estimates of disease-free survival probabilities after complete remission stratified for each post-remission therapy (PRT) score group in 452 patients of the AML96 trial. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from favourable to unfavourable score group. The 95% confidence intervals for 3-year survival are given in the brackets. Fav. is the abbreviation of Favourable, Interm. of Intermediate, and Unfav. of Unfavourable

3 Favourable-score group, 3-year survival: 0 52 [0 45; 0 58] Intermediate-score group, 3-year survival: 0 50 [0 40; 0 60] Probability of disease-free survival Unfavourable-score group, 3-year survival: 0 32 [0 15; 0 50] Score groups with number at risk Fav Interm Unfav Supplementary Figure 1B: Kaplan-Meier estimates of disease-free survival probabilities after complete remission stratified for each post-remission therapy (PRT) score group in 407 patients of the AML2003 trial. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from favourable to unfavourable score group. The 95% confidence intervals for 3-year survival are given in the brackets. Fav. is the abbreviation of Favourable, Interm. of Intermediate, and Unfav. of Unfavourable

4 Favourable-score group, 3-year survival: 0 55 [0 41; 0 67] Intermediate-score group, 3-year survival: 0 41 [0 30; 0 52] Unfavourable-score group, 3-year survival: 0 19 [0 08; 0 34] Score groups with number at risk Fav Interm Unfav Supplementary Figure 2A: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy (PRT) score group in 160 patients of the AML96 trial treated with chemotherapy. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from favourable to unfavourable score group. The 95% confidence intervals for 3-year survival are given in the brackets. Fav. is the abbreviation of Favourable, Interm. of Intermediate, and Unfav. of Unfavourable

5 Favourable-score group, 3-year survival: 0 66 [0 54; 0 76] Intermediate-score group, 3-year survival: 0 62 [0 50; 0 72] Unfavourable-score group, 3-year survival: 0 07 [0 005; 0 28] Score groups with number at risk Fav Interm Unfav Supplementary Figure 2B: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy (PRT) score group in 157 patients of the AML96 trial treated with autologous haematopoietic stem cell transplantation. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from favourable to unfavourable score group. The 95% confidence intervals for 3-year survival are given in the brackets. Fav. is the abbreviation of Favourable, Interm. of Intermediate, and Unfav. of Unfavourable

6 Favourable-score group, 3-year survival: 0 82 [0 69; 0 89] Intermediate-score group, 3-year survival: 0 44 [0 31; 0 56] Unfavourable-score group, 3-year survival: 0 33 [0 14; 0 55] Score groups with number at risk Fav Interm Unfav Supplementary Figure 2C: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy (PRT) score group in 135 patients of the AML96 trial treated with allogeneic haematopoietic stem cell transplantation. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from favourable to unfavourable score group. The 95% confidence intervals for 3-year survival are given in the brackets. Fav. is the abbreviation of Favourable, Interm. of Intermediate, and Unfav. of Unfavourable

7 Autologous HSCT, 3-year survival: 0 76 [0 51; 0 90] Allogeneic HSCT, 3-year survival: 0 71 [0 58; 0 81] Chemotherapy, 3-year survival: 0 67 [0 57; 0 75] Therapies with number at risk Auto Allo Chemo Supplementary Figure 3A: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy in 265 patients of the AML2003 trial with favourable post-remission therapy (PRT) score group. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from chemotherapy to autologous to allogeneic HSCT. The 95% confidence intervals for 3-year survival are given in the brackets. HSCT is the abbreviation of haematopoietic stem cell transplantation, Auto. of Autologous HSCT, Allo. of Allogeneic HSCT, and Chemo. of Chemotherapy

8 Autologous HSCT, 3-year survival: 0 67 [0 19; 0 90] Allogeneic HSCT, 3-year survival: 0 63 [0 43; 0 78] Chemotherapy, 3-year survival: 0 59 [0 43; 0 72] Therapies with number at risk Auto Allo Chemo Supplementary Figure 3B: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy in 114 patients of the AML2003 trial with intermediate post-remission therapy (PRT) score group. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from chemotherapy to autologous to allogeneic HSCT. The 95% confidence intervals for 3-year survival are given in the brackets. HSCT is the abbreviation of haematopoietic stem cell transplantation, Auto. of Autologous HSCT, Allo. of Allogeneic HSCT, and Chemo. of Chemotherapy

9 Autologous HSCT, 3-year survival: not observed Allogeneic HSCT, 3-year survival: 0 26 [0 02; 0 64] Chemotherapy, 3-year survival: 0 50 [0 22; 0 72] Therapies with number at risk Auto Allo Chemo Supplementary Figure 3C: Kaplan-Meier estimates of overall survival probabilities after complete remission stratified for each post-remission therapy in 28 patients of the AML2003 trial with unfavourable post-remission therapy (PRT) score group. Small vertical bars represent the censoring times of patients who were alive at their last follow-up. At 1, 3, and 5 years, horizontal crossbars indicate the upper and lower limits of 95% confidence intervals for the estimated survival probabilities. Crossbars increase from chemotherapy to allogeneic HSCT. The 95% confidence intervals for 3-year survival are given in the brackets. HSCT is the abbreviation of haematopoietic stem cell transplantation, Auto. of Autologous HSCT, Allo. of Allogeneic HSCT, and Chemo. of Chemotherapy

10 Study Alliance Leukaemia (SAL) Investigators of the AML96 trial B. Dörken, D. Huhn, O. Knigge (Charité Campus Virchow, Berlin), O. Rick, W. Siegert (Charité Campus Mitte, Berlin), J. Hesse-Amojo (Krankenhaus Spandau, Berlin), R. Kolloch, U. Krümpelmann (Krankenanstalten Gilead, Bielefeld), K.-H. Pflüger, T. Wolff (Evang. Diakonie-Krankenhaus Bremen), H.-H. Heidtmann (St. Joseph-Hospital, Bremerhaven), F. Marquard (Allgemeines Krankenhaus, Celle), M. Hänel, F. Fiedler, R. Herbst (Klinikum Chemnitz), M. Gramatzki, G. Helm (Universitätsklinikum, Erlangen), D. Beelen (Universitätsklinikum, Essen), J.-G. Saal (Malteser Krankenhaus, Flensburg, H.-G. Höffkes, M. Arland (Städtisches Klinikum Fulda), J. Finke (Universitätsklinikum, Freiburg), E. Fasshauer (St. Elisabeth- Krankenhaus, Halle), A. Zander (Universitätsklinikum Eppendorf, Hamburg), N. Schmitz, R. Stuhlmann (Asklepios Klinik St. Georg, Hamburg), H. Schmidt, K. Buhrmann (Kreiskrankenhaus, Hameln), H. Dürk (St. Marien-Hospital, Hamm), M. Burk (Klinikum Stadt, Hanau), A. Ganser (Medizinische Hochschule, Hannover), A. Ho, A. Krämer (Universitätsklinikum Heidelberg), A. A. Fauser (Klinik f. Hämatologie/Onkologie und KMT, Idar-Oberstein), U. Kaiser, A. Bartholomäus (St. Bernward Krankenhaus Hildesheim), H. Link, F.-G. Hagmann (Westpfalzklinikum, Kaiserslautern), G. Köchling (Kreiskrankenhaus, Leer), K.-P. Schalk (St. Vincent- Krankenhaus, Limburg/Lahn), S. Fetscher (Städtisches Krankenhaus Süd, Lübeck), T. Wagner (Universitätsklinikum, Lübeck), A. Neubauer (Uniklinik Marburg, Marburg), H. Bodenstein, J. Tischler (Klinikum Minden), H.-J. Kolb (Klinikum Großhadern, München), H. Pohlmann, N. Brack (Städtisches Krankenhaus München-Harlaching, München), H. Wandt, K. Schäfer-Eckart (Klinikum Nord, Nürnberg), B. Seeber (Klinikum Offenbach, Offenbach), F. Hirsch (Kreiskrankenhaus, Offenburg), T. Geer, H. Heißmeyer (Diakonie-Krankenhaus, Schwäbisch-Hall), J. Labenz (Ev. Jung-Stilling-Krankenhaus, Siegen), W. Aulitzky, M. Kaufmann (Robert-Bosch-Krankenhaus Stuttgart), J. Kaesberger (Diakonissen-Krankenhaus, Stuttgart), M. R. Clemens, R. Mahlberg (Mutterhaus der Borromaerinnen, Trier), L. Kanz (Universitätsklinikum, Tübingen), R. Schwerdtfeger (Deutsche Klinik für Diagnostik, Wiesbaden), R. Engberding, R. Winter (Stadtkrankenhaus, Wolfsburg), M. Sandmann (Kliniken St. Antonius, Wuppertal), H. Einsele, H. Rückle-Lanz (Universitätsklinikum Würzburg), and L. Greiner (Städtisches Klinikum Wuppertal, Wuppertal)